MP-0621 / Molecular Partners - LARVOL DELTA

MP0621 (cKit x CD16a x CD47), a Multi-Specific Switch-Darpin with Conditional Blockade of CD47 Targeting Hematopoietic Stem Cells: Preclinical Evaluation of a Next-Generation Conditioning Agent for Stem Cell Transplantation (ASH 2024) - "The blockade of CD47 exclusively on target cells allows MP0621 to enhance efficacy of cKit-targeting, while reducing off-target effects seen with systemic anti-CD47 blockade. Thus, MP0621 represents a potential novel targeted treatment approach for conditioning that could improve the benefit/risk profile of current HSCT strategies for patients."

Preclinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Transplantation • CD34 • CD47 • FCGR3A

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition (GlobeNewswire) - "The poster to be presented at ASH 2024 will provide a clinical update of the ongoing first-in-human dose-escalation phase 1/2a study of MP0533 in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)/AML. MP0533 showed an acceptable safety profile in the first 7 dose cohorts, with the majority of adverse events reported being infusion-related reactions and cytokine release syndrome; The poster to be presented at ASH 2024 builds on the data presented earlier this year at the European Haematology Association 2024 Congress and provides further preclinical in vivo proof-of-mechanism data, demonstrating that MP0621 could be an efficient next-generation conditioning regimen for autologous HSCT."

P1/2 data • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Myelodysplastic Syndrome • Oncology

C-KIT X CD16A X CD47 SWITCH-DARPIN WITH CONDITIONAL BLOCKADE OF CD47: A NEXT-GENERATION TARGETED CONDITIONING FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (EHA 2024) - "In summary, our preclinical results indicate that the c-KIT x CD16a x CD47 Switch-DARPin candidate may be aneffective means to specifically eliminate c-KIT+ HSCs with a suitable pharmacokinetic profile for a conditioningagent. The conditionally masked CD47 moiety allows to harness additional efficacy gained by blocking CD47on target cells while avoiding CD47-related off-target effects. Therefore, this Switch-DARPin presents a noveltargeted conditioning approach that may improve the risk/benefit profile of HSCT strategies for patients withAML as well as non-malignant indications."

Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Transplantation • FCGR3A • KIT • SIRPA

MOLECULAR PARTNERS REPORTS CORPORATE HIGHLIGHTS FROM Q4 2023 AND KEY FINANCIALS FOR FULL YEAR 2023 (Molecular Partners Press Release) - "Data from the Phase 1/2a trial of MP0533, including safety and efficacy, to be presented in H1 2024; expansion of enrollment to higher dose cohorts planned in H2 2024; Initial preclinical data from first Switch-DARPin program cKIT x CD16a x CD47 expected in H1 2024; preclinical proof-of-concept studies expected in H2 2024, which should provide strong translational efficacy data; The full dataset from the MP0317 Phase 1 dose-escalation trial expected in H1 2024."

P1/2 data • Preclinical • Trial status • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology